Genetic determinants of circulating sphingolipid concentrations in European populations by Hicks, A.A. (Andrew) et al.
Genetic Determinants of Circulating Sphingolipid
Concentrations in European Populations
Andrew A. Hicks1.,Peter P. Pramstaller1,2,3."*, A˚sa Johansson4.,Veronique Vitart5., Igor Rudan6,7,8.",Peter
Ugocsai9.,Yurii Aulchenko10.,Christopher S. Franklin6,Gerhard Liebisch9, Jeanette Erdmann11, Inger Jonasson4,
Irina V. Zorkoltseva12,Cristian Pattaro1,Caroline Hayward5,AaronIsaacs10,Christian Hengstenberg13,Susan
Campbell5,Carsten Gnewuch9,A. CecileJ.W.Janssens10,Anatoly V. Kirichenko12, Inke R. Ko¨nig14,Fabio Marroni1,
OzrenPolasek8,15,Ayse Demirkan10, Ivana Kolcic15,ChristineSchwienbacher1,16,Wilmar Igl4,Zrinka Biloglav15,
Jacqueline C.M. Witteman10, Irene Pichler1,Ghazal Zaboli4,Tatiana I. Axenovich12, Annette Peters17, Stefan
Schreiber18,H.-Erich Wichmann17,19,Heribert Schunkert11,Nick Hastie5,Ben A. Oostra20,Sarah H. Wild6,Thomas
Meitinger21",UlfGyllensten4",Cornelia M. van Duijn10", James F.Wilson6",AlanWright5",Gerd Schmitz9",Harry
Campbell6"*
1 Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy, Affiliated Institute of the University of Lu¨beck, Lu¨beck, Germany, 2Department of
Neurology, General Central Hospital, Bolzano, Italy, 3Department of Neurology, University of Lu¨beck, Lu¨beck, Germany,4Department of Genetics and Pathology, Rudbeck Laboratory,
Uppsala University, Uppsala, Sweden, 5MRC Human Genetics Unit, IGMM, Western General Hospital, Edinburgh, United Kingdom, 6Centre for Population Health Sciences, University
of Edinburgh, Edinburgh, United Kingdom, 7Croatian Centre for Global Health, Faculty of Medicine, University of Split, Split, Croatia, 8Gen-info Ltd, Zagreb, Croatia, 9 Institute for
Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany, 10Department of Epidemiology, Erasmus University Medical Center, Rotterdam,
The Netherlands, 11Medizinische Klinik II, University of Lu¨beck, Lu¨beck, Germany, 12 Institute of Cytology and Genetics SD RAS, Novosibirsk, Russia, 13Klinik und Poliklinik fu¨r Innere
Medizin II, Universita¨t Regensburg, Regensburg, Germany, 14 Institut fu¨r Medizinische Biometrie und Statistik, University of Lu¨beck, Lu¨beck, Germany, 15Andrija Stampar School of
Public Health, Faculty of Medicine, University of Zagreb, Zagreb, Croatia, 16Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy, 17 Institute of
Epidemiology, Helmholtz Zentrum Mu¨nchen – German Research Center for Environmental Health, Neuherberg, Germany, 18 Institut fu¨r Klinische Molekularbiologie, Christian-
Albrechts Universita¨t, Kiel, Germany,19 Institute of Medical Information Science, Biometry and Epidemiology, Chair of Epidemiology, LMU Munich, Germany,20Department of Clinical
Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands, 21Helmholtz Zentrum Mu¨nchen, Neuherberg, Munich, Germany
Abstract
Sphingolipids have essential roles as structural components of cell membranes and in cell signalling, and disruption of their
metabolism causes several diseases, with diverse neurological, psychiatric, and metabolic consequences. Increasingly, variants
within a few of the genes that encode enzymes involved in sphingolipid metabolism are being associated with complex disease
phenotypes. Direct experimental evidence supports a role of specific sphingolipid species in several common complex chronic
disease processes including atherosclerotic plaque formation, myocardial infarction (MI), cardiomyopathy, pancreatic b-cell
failure, insulin resistance, and type 2 diabetes mellitus. Therefore, sphingolipids represent novel and important intermediate
phenotypes for genetic analysis, yet little is known about the major genetic variants that influence their circulating levels in the
general population. We performed a genome-wide association study (GWAS) between 318,237 single-nucleotide
polymorphisms (SNPs) and levels of circulating sphingomyelin (SM), dihydrosphingomyelin (Dih-SM), ceramide (Cer), and
glucosylceramide (GluCer) single lipid species (33 traits); and 43 matched metabolite ratios measured in 4,400 subjects from five
diverse European populations. Associated variants (32) in five genomic regions were identified with genome-wide significant
corrected p-values ranging down to 9.08610266. The strongest associations were observed in or near 7 genes functionally
involved in ceramide biosynthesis and trafficking: SPTLC3, LASS4, SGPP1, ATP10D, and FADS1–3. Variants in 3 loci (ATP10D, FADS3,
and SPTLC3) associate with MI in a series of three German MI studies. An additional 70 variants across 23 candidate genes
involved in sphingolipid-metabolizing pathways also demonstrate association (p= 1024 or less). Circulating concentrations of
several key components in sphingolipid metabolism are thus under strong genetic control, and variants in these loci can be
tested for a role in the development of common cardiovascular, metabolic, neurological, and psychiatric diseases.
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Introduction
Sphingolipids are essential components of plasma membranes
and endosomes and are believed to play critical roles in cell surface
protection, protein and lipid transport and sorting, and cellular
signalling cascades. They are known to have roles in both health
and disease [1,2]. Several rare monogenic diseases associated with
sphingolipid biosynthesis and turnover have been identified such
as metachromatic leukodystrophy and GM1- and GM2-ganglio-
sidosis, Niemann-Pick, Gaucher, Krabbe, Fabry, Farber, Tay-
Sachs and Sandhoff diseases [3]. Defective biosynthesis due to
mutations in genes involved in sphingolipid metabolism (e.g.serine
palmitoyl transferase (SPTLC1) [4]; ceroid-lipofuscinosis, neuronal
8 (CLN8) [5]; and ceramide synthase (LASS1) [6]) can also lead to
disease. Moreover, natural fungal inhibitors of ceramide synthase
can result in a broad spectrum of effects including equine
leucoencephalomalacia, porcine pulmonary oedema syndrome
and liver cancer in rats [7], demonstrating the wide range of
processes that include cell proliferation, differentiation and
apoptosis underpinned by sphingolipid metabolism. Identifying
common genetic variants that influence the balance between
individual sphingolipid concentrations represents an important
step towards understanding the contribution of sphingolipids to
common human disease. To achieve this goal, we conducted a
genome-wide association study (GWAS) on plasma levels of 33
major sphingolipid species (24 sphingomyelins and 9 ceramides) in
five European populations, both within and across populations.
The traits were analysed by individual species (sphingomyelins
(SM), dihydrosphingomyelins (Dih SM), ceramides (Cer) and
glucosylceramides (GluCer)) or aggregated into groups of species
with similar characteristics (e.g. unsaturated ceramides), and
expressed as absolute concentrations or as molar percentages
within sphingolipid classes (mol%). In addition we examined 43
matched metabolite ratios between the traits as a surrogate for
enzyme activity [8] in separate clusters designed to examine
sphingolipid metabolism (11 ratios), desaturation (16 ratios) and
elongation (16 ratios). All traits displayed substantial heritabilities
in that much of the observed variation in sphingolipid levels could
be attributed to genetic variation among individuals in each
population.
Results
The GWAS for single species and matched metabolite ratios
revealed a total of 32 SNPs in five distinct loci reaching genome-
wide significance (p values ranging down to 9.08610266) (Table 1,
Figure 1 and Figure 2, and Table S1 and Table S3). The direction
and magnitude of the observed effect sizes for the 22 variants
identified in the analysis of single species are summarized in
Table 1 with full details in Table S1. For three of the regions
(chromosomal regions 4p12, 14q23.2 and 19p13.2), p values
reached genome-wide significance in the largest cohort (South
Tyrol), and the effect was replicated in the other populations. For
two additional loci (11q12.3 and 20p12.1), signals bordered on
genome-wide significance in South Tyrol alone, were consistent
between all 5 populations and reached genome-wide significance
in the meta-analysis. In the single species analysis, the strongest
associations for three of the loci (11q12.3, 14q23.2 and 19p13.2)
were found with sphingomyelins and dihydrosphingomyelins. The
4p12 locus showed the strongest association with serum gluco-
sylceramides and the 20p12.1 locus showed the strongest
association with serum ceramide concentrations. Table S2 shows
the p-values for the individual SNPs when included in a multiple
regression model, and the fraction of single sphingolipid variance
explained by sex, age and all SNPs in the model together. Taken
together, the SNPs explain up to 10.1% of the population
variation in each trait. Ratios of matched (substrate/product) pairs
have been shown to reduce variation in the dataset and increase
power of association several orders of magnitude [8]. Analysis of
43 matched metabolite ratios (Table S3) indeed increased power of
association up to 10 orders of magnitude on some of the 22
variants above, and revealed an additional 10 SNPs over the same
7 genes reaching statistical significance (see Table S3). Surprisingly
no signals from new genes reached genome-wide significance,
highlighting the fact that across the 5 cohorts analysed here, the 7
genes identified are the major genes associated with circulating
sphingolipid concentrations. Among the 32 significant individual
SNPs (Table S4) variants in LASS4 explain up to 7.5% of the
variance in some ratios (i.e. in SM16:0/SM18:0), SGPP1 variants
explain up to 12.7% of the variance (i.e in SM14:0/SM16:0),
FADS1–3 variants explain up to 3.5% of the variance (e.g. in
SM16:0/SM16:1), SPTLC3 variants explain up to 4.9% of the
variance (e.g. in SM14:0/SM16:0 and SM24:0/Cer24:0), and
ATP10D variants up to 4.2% of GluCer/Cer variance. Combined
effects of several genes (i.e. SPTLC3 and SGPP1) explains up to
14.2% of the variance in medium chain SM ratios (SM14:0/
SM16:0) and, in combination with LASS4, up to 11.2% of the
variance in long-chain sphingomyelin ratios (SM22:0/SM24:0).
All SNPs within the associated chromosomal regions are located
within or are in linkage disequilibrium (LD) with genes that encode
enzymes involved in sphingolipid biosynthesis or intracellular
transport (Figure 2). The ATPase, class IV, type 10D (ATP10D)
gene, located at chromosome 4p12, encodes a putative serine-
phospholipid (phosphatidylserine, ceramide) translocase [9]. Three
SNPs at this locus showed genome-wide significant associations
with glucosylceramides (C16:0, C24:1) (Table 1, Table S1), with
an additional five variants revealed in the ratio analysis (Table S3).
SNP rs10938494 gave the strongest association in the single
species analysis (p-values of 1.6861029 in South Tyrol and
8.03610219 in the joint analysis), and was among the strongest
association in the ratio analysis (p= 3.04610216) along with
rs2351791 (p= 6.58610217).
Three fatty-acid desaturase genes (FADS1, 2 and 3) are located
adjacent to one another in a cluster at the 11q12.3 locus. The
FADS1–3 genes encode enzymes that regulate the desaturation of
fatty acids by the introduction of double bonds between defined
carbons of the fatty acyl chain. Seven SNPs at this locus,
distributed in and around the three genes, reached statistical
significance in the single species analysis for sphingomyelin 16:1
levels in the joint analysis, with p-values ranging from 2.99610211
(rs174449, close to FADS3) to 6.60610213 (rs1000778, in FADS3)
(Table 1). The ratio analysis revealed an additional SNP at this
locus within the FADS3 gene (rs174450, Table S3), and improved
association results for other SNPs several orders of magnitude (e.g.
rs1000778 p= 1.29610215). Fatty acids are built into ceramides by
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the ceramide synthases (e.g. LASS4). Unsaturated ceramides can be
synthesized exclusively by the introduction of unsaturated fatty
acids into the sphingosine/sphinganine chain. The pivotal role of
FADS1–3 in the synthesis of unsaturated ceramides is confirmed by
the strong associations of SNPs in this cluster to the mono-
unsaturated sphingomyelins 16:1, 18:1 and 20:1, which are the
end-products of the ceramide biosynthesis pathway (Table 1,
Table S1), and the ratios between these and their respective
unsaturated precursors (Table S3). Previous studies of sphingolipid
metabolites and poly-unsaturated fatty acids (PUFA) have
demonstrated associations to SNPs, including rs174537, over the
FADS1 and FADS2 genes in several populations [8,10,11].
The sphingosine-1-phosphate phosphohydrolase 1 gene (SGPP1)
at the 14q23.2 locus belongs to the super-family of lipid
phosphatases that catalyze the generation of sphingosine and,
together with irreversible cleavage by sphingosine-1-phosphate
(S1P)-lyase, strongly influences the pathway of S1P to ceramide
(Figure 3). Six SNPs in and around this gene demonstrate the most
significant associations with circulating sphingomyelin C14–C16/
C22–C24 and dihydrosphingomyelin concentrations (Table 1) in
the single species analysis, with a further two SNPs revealed in the
ratio analysis. SNP rs7157785 showed the strongest association
with sphingomyelin 14:0 relative content (molar percentage:
mol%) with genome-wide significant p-values in all five popula-
tions, particularly in the South Tyrol population (p= 2.53610228)
and joint analysis (p= 9.08610266), and demonstrated the most
significant association in the ratio analysis. Enhanced SGPP1
activity leads to elevated ceramide levels by shifting the
stochiometric balance of SGPP1/S1P-lyase towards sphingosine
and ceramide production.
Five SNPs at the 19p13.2 locus showed some of the strongest
associations with sphingolipids and all lie within LASS4, the gene
encoding LAG1 longevity assurance homologue 4. In the single
species analysis SNP rs7258249 showed the highest genome-wide
significant association with sphingomyelin 18:0 mol% (South
Tyrol p= 1.04610215 and joint analysis p= 2.28610227). Several
LASS4 SNPs showed statistically significant association with the
sphingomyelin species C18 to C20 and with ceramide C20:0
(Table 1 and Table S1). In the ratio analysis, however, associations
strengthened by several orders of magnitude (p value) over those
with these SNPs, with rs1466448 demonstrating the most
statistically significant association (p= 4.05610235). LASS family
members, six of which have been identified in mammals (LASS1–
6), are de novo ceramide synthases (CerS) that synthesize
dihydroceramide from sphinganine and fatty acid (Figure 3).
Moreover, LASS enzymes catalyze the re-synthesis of ceramide
and phytoceramide from sphingosine and phytosphingosine
respectively, which are cleavage products of alkaline ceramidase
activity in endoplasmic reticulum (ER) membranes.
The 20p12.1 locus contains the serine palmitoyltransferase long
chain base subunit 3 gene (SPTLC3) encoding a functional subunit
of the SPT enzyme-complex that catalyzes the first and rate-
limiting step of de novo sphingolipid synthesis. One SNP (rs680379)
demonstrated association for unsaturated ceramide in the South
Tyrol population alone (p= 1.77610207) and was genome-wide
significant in the joint analysis (p= 8.24610215). Significant
association was observed also with C16 to C24 ceramides and
the sphingomyelins 16:1 and 17:0 (Table 1 and Table S1). The
ratio analysis strengthened association at this variant
(p= 3.3610220 for the metabolite ratio SM24:0/Cer24:0) and
revealed two further significant variants at this locus (rs3848751
and rs6078866, Table S3).
As matched metabolite ratios can serve as a proxy for enzyme
activity [8], in a complementary candidate gene approach, we
investigated association signals in our combined single species and
ratio datasets at 624 SNPs within or near 40 genes that encode
enzymes involved in sphingolipid metabolism, in order to identify
the most promising variants within these genes for further analysis.
Of these, a total of 70 variants in or near 23 of the genes
demonstrate association p values of 1024 or less (Table S5).
Sex and age adjusted single sphingolipids species displayed
strong phenotypic correlations with circulating plasma lipoproteins
especially with total cholesterol or LDL-cholesterol (Table S6, e.g.
between the sum of saturated sphingomyelin species and total
cholesterol: 0.788/0.717/0.794/0.733/0.773 in respectively
NPHS/ERF/SOUTH TYROL/CROATIA/ORKNEY; or
SM16:1 and total cholesterol 0.737/0.631/0.671/0.6/0.638). This
is in agreement with recent lipid profiling of lipoprotein fractions,
showing higher proportions of sphingomyelin and ceramides in the
LDL fraction [12]. However, among the GWAS hits uncovered in
this analysis, only the FADS1–3 cluster overlaps with those
reported in large meta-analysis of circulating serum lipoproteins
levels (strongest with total and LDL-cholesterol levels) [13].
Several of the variants reported here display suggestive associa-
tions with classical lipids in the EUROSPAN cohorts (Table S7).
All eight SNPs in the FADS1–3 cluster associate with HDL-
cholesterol levels (age-sex adjusted p values between 0.06 and
0.0041) similar to previous observations [8]. Interestingly, the sex-
specific age-adjusted results show that these associations seem
driven by the association found in males (lowest p= 0.0037 at
rs174546). Association with HDL-cholesterol in males is also seen
with SNPs in ATP10D (rs2351791, p= 0.01) and SPTLC3
(rs3848751, p= 0.0047). SNPs at ATP10D also associate with
LDL-cholesterol, albeit weakly in the total population (rs469463,
p= 0.034). In the males only, variants at LASS4 (rs28133,
p= 0.043) and SPTLC3 (rs3848751, p= 0.022 and rs6078866,
p= 0.02) also associate weakly with LDL-cholesterol levels. Five
variants in FADS1–3 and two in ATP10D associate with
triglyceride levels, with lower p values in males than in the whole
group (p values from 0.017 to 0.009 in FADS1–3 and 0.0071 for
Author Summary
Although several rare monogenic diseases are caused by
defects in enzymes involved in sphingolipid biosynthesis
and metabolism, little is known about the major variants
that control the circulating levels of these important
bioactive molecules. As well as being essential compo-
nents of plasma membranes and endosomes, sphingolip-
ids play critical roles in cell surface protection, protein and
lipid transport and sorting, and cellular signalling cascades.
Experimental evidence supports a role for sphingolipids in
several common complex chronic metabolic, cardiovascu-
lar, or neurological disease processes. Therefore, sphingo-
lipids represent novel and important intermediate pheno-
types for genetic analysis, and discovering the genetic
variants that influence their circulating concentrations is
an important step towards understanding how the genetic
control of sphingolipids might contribute to common
human disease. We have identified 32 variants in 7 genes
that have a strong effect on the circulating plasma levels of
33 distinct sphingolipids, and 43 matched metabolite
ratios. In a series of 3 German MI studies, we see
association with MI for variants in 3 of the genes tested.
Further cardiovascular, metabolic, neurological, and psy-
chiatric disease associations can be tested with the
variants described here, which may identify additional
disease risk and potentially useful therapeutic targets.
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Table 1. Variants Significantly Associated with Circulating Sphingolipid Concentrations.
Chr Region SNP Effect Allele Position
Lipid Species With Significant
Associations Within the Region South Tyrol (n= 1097) Swedish (n =656)
P-Value range P-Value range
4p12 (ATP10D) rs10938494 A 47258205 GluCer16:0, GluCer24:1, GluCer 6.761028–3.3610213 7.361022–4.761024
4p12 (ATP10D) rs2351791 A 47277144 GluCer16:0, GluCer24:1, GluCer 2.861026–2.9610212 0.039–1.161024
4p12 (ATP10D) rs4695267 G 47367058 GluCer16:0, GluCer24:1, GluCer 0.009–5.661027 0.013–2.061023
11q12.3 (FADS) rs174537 A 61309256 SM 16:1, 18:1, 20:1 0.019–3.661024 0.028–2.761024
11q12.3 (FADS) rs102275 G 61314379 SM 16:1, 18:1, 20:1 0.013–2.261024 0.028–2.661024
11q12.3 (FADS) rs174546 A 61326406 SM 16:1, 18:1, 20:1 0.011–2.961024 0.028–2.761024
11q12.3 (FADS) rs174556 A 61337211 SM 16:1, 18:1, 20:1 7.761023–8.261025 0.01–1.961024
11q12.3 (FADS) rs1535 G 61354548 SM 16:1, 18:1, 20:1 8.761023–6.861024 0.028–2.161023
11q12.3 (FADS) rs174449 G 61396955 SM 16:1, 18:1, 20:1 6.961023–3.961025 0.36–2.261024
11q12.3 (FADS) rs1000778 A 61411881 SM 16:1, 18:1, 20:1 5.361023–6.361027 0.11–0.014
14q23.2 (SGPP1) rs4902242 G 63299842 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.15–1.7610220 0.35–4.9610210
14q23.2 (SGPP1) rs7157785 A 63305309 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.02–2.5610228 0.79–4.3610211
14q23.2 (SGPP1) rs1959033 A 63405339 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.24–1.8610210 0.97–5.661023
14q23.2 (SGPP1) rs4459477 A 63415943 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.18–8.1610216 0.47–7.661026
14q23.2 (SGPP1) rs12889954 G 63457221 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.014–6.1610221 0.54–7.361024
14q23.2 (SGPP1) rs12881815 A 63674348 SM14:0, 15:0, 23:0, 24:0, 22:1, 24:1,
dihSM16:0, 18:0
0.94–7.661023 0.90–3.361027
19p13.2 (LASS4) rs7258249 G 8177721 SM18:0, 18:1, 20:0, 20:1, Cer20:0 0.056–1.0610215 0.27–8.961024
19p13.2 (LASS4) rs11666866 A 8191607 SM18:0, 18:1, 20:0, 20:1, Cer20:0 0.22–7.0610211 0.35–4.061023
19p13.2 (LASS4) rs1466448 C 8195519 SM18:0, 18:1, 20:0, 20:1, Cer20:0 0.79–4.2610212 0.037–1.461025
19p13.2 (LASS4) rs2967625 A 8204411 SM18:0, 18:1, 20:0, 20:1, Cer20:0 0.65–3.161029 0.50–9.161024
19p13.2 (LASS4) rs28133 A 8233502 SM18:0, 18:1, 20:0, 20:1, Cer20:0 0.051–4.761025 0.86–3.861024
20p12.1 (SPTLC3) rs680379 A 12917400 Cer16:0, 22:0, 23:0, 24:0, 24:1, CerSat,
CerUnsat, SM17:0, SM16:1
3.561024–1.861027 0.49–0.035
Orkney (n=719) Croatia (n=720) Erf (n = 918) Joint (n =4110) Effect Direction Effect Direction
P-Value range P-Value range P-Value range P-Value range Positive Beta Negative Beta
0.12–6.361023 0.12–1.461023 3.561024–5.761026 6.3610212–8.0610219 GluCer16:0, GluCer24:1, GluCer
0.22–0.014 0.33–0.01 1.261025–4.461028 1.5610211–4.6610218 GluCer16:0, GluCer24:1, GluCer
0.18–0.04 0.087–0.01 3.361024–8.161026 4.961028–2.4610212 GluCer16:0, GluCer24:1, GluCer
0.051–3.361023 0.24–3.261024 0.065–1.661024 2.461027–9.0610212 SM 16:1, 18:1, 20:1
0.073–2.861023 0.19–8.261024 0.11–4.861024 3.061027–2.2610211 SM 16:1, 18:1, 20:1
0.073–2.861023 0.18–7.361024 0.078–1.661024 2.461027–2.0610211 SM 16:1, 18:1, 20:1
9.261023–4.961024 0.28–3.561024 0.082–5.661025 8.961025–3.7610212 SM 16:1, 18:1, 20:1
0.054–3.961023 0.28–3.561024 0.067–7.561024 4.261027–1.6610211 SM 16:1, 18:1, 20:1
0.21–2.961024 0.41–3.161024 0.12–0.014 3.361027–3.0610211 SM 16:1, 18:1, 20:1
0.04–6.261025 0.05–3.061023 0.015–4.161023 6.661027–6.6610213 SM 16:1, 18:1, 20:1
0.37–1.5610210 0.93–1.9610213 0.34–8.061027 0.053–2.3610234 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0, 18:0
0.66–2.9610215 0.31–5.8610211 0.60–5.261028 4.961023–9.1610266 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0, 18:0
0.75–8.161024 0.17–7.861023 0.76–7.261023 1.461023–6.6610213 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0, 18:0
0.99–4.761025 0.69–1.261027 0.63–6.361025 0.33–8.3610229 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0, 18:0
0.69–4.161026 0.53–6.461029 0.29–2.461027 4.161023–2.9610233 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0, 18:0
0.99–0.026 0.98–1.761027 0.73–7.861023 0.83–7.7610210 SM14:0, 15:0, 22:1 SM23:0, 24:0, 24:1, dihSM16:0,
18:0
0.94–9.661024 0.001–2.261027 0.011–9.761027 1.161029–2.3610227 SM18:0, 18:1, 20:0, 20:1, Cer20:0
0.21–1.661027 0.77–6.361025 0.68–1.161023 7.861026–6.7610221 SM18:0, 18:1, 20:0, 20:1, Cer20:0
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rs17462424 in ATP10D). Association of FADS variants with
triglyceride levels has also been observed in other populations
[8]. As previously highlighted [8], the p values for association with
the sphingolipids species were orders of magnitude stronger than
with these classical lipids.
Given the reported associations to classical lipids and cardiovas-
cular disease with variants at the FADS1–3 locus [10,13,14], and the
evidence from functional studies of a role for sphingolipids in
atherosclerotic plaque formation and lipotoxic cardiomyopathy
[15], we looked in silico in a series of three age- and sex-adjusted
GWAS datasets of German myocardial infarction (MI) case-control
studies (Ger MIFS I [16] Ger MIFS II [17] and Ger MIFS III
(KORA), unpublished) for evidence of association with the major
variants associating with sphingolipid concentrations. Variants
within three of the genes (ATP10D, FADS3 and SPTLC3) associate
with MI in one or more of the studies (Table 2). The protective odds
ratios observed for variants in ATP10D and SPTLC3 are on alleles
correlating positively with higher metabolite/lower ceramide ratios
(i.e. GluCer/Cer and SM/Cer), in support of evidence that
increased enzyme/transporter activity that lowers ceramide levels
might alleviate the pro-apoptotic effects seen with higher ceramide
levels in cardiomyocytes [18]. As previously hypothesised, carriers of
FADS variants that are associated with higher desaturase activity
may be prone to a proinflammatory response favoring atheroscle-
rotic vascular damage [14].
Discussion
Direct experimental evidence indicates a role for sphingolipids
in several common complex chronic disease processes including
Orkney (n=719) Croatia (n=720) Erf (n = 918) Joint (n =4110) Effect Direction Effect Direction
P-Value range P-Value range P-Value range P-Value range Positive Beta Negative Beta
0.028–7.561027 0.51–1.361028 0.67–5.861024 1.861025–4.8610225 SM18:0, 18:1, 20:0, 20:1, Cer20:0
0.48–5.661024 0.80–0.022 0.14–5.261023 1.261024–3.4610215 SM18:0, 18:1, 20:0, 20:1, Cer20:0
0.31–3.761025 0.78–1.061023 0.74–0.053 0.031–4.9610211 SM18:0, 18:1, 20:0, 20:1, Cer20:0
0.10–5.261025 0.045–3.661024 0.03–8.361028 2.261028–8.2610215 Cer22:0, 23:0, 24:0, 24:1, CerSat,
CerUnsat, SM17:0
Cer16:0,SM16:1
22 variants in 7 genes located in 5 distinct chromosomal locations demonstrate genome-wide significant association signals with several measured single sphingolipid
species (listed). The p-value ranges for significant signals across the sphingolipid species are shown for each population separately and jointly, and the direction of the
association effects, as derived from the standardized regression coefficient (b), is summarized. Detailed results for each species along with specific b values are shown in
Table S1. Abbreviations sphingomyelin (SM), dihydrosphingomyelin (dihSM), ceramide (Cer) and glucosylceramide (GluCer) unsaturated ceramides (CerUnsat), saturated
ceramides (CerSat). In the nomenclature (e.g. SM18:0), the number before the colon refers to length of the carbon chain and the number after the colon to the number
of double bonds in the chain. Additional variants uncovered in the matched metabolite ratio analysis can be found in Table S3. Alleles correspond to Illumina TOP
notation.
doi:10.1371/journal.pgen.1000672.t001
Table 1. Cont.
Figure 1. Genome-wide association results for sphingolipids. Manhattan plots show the association signals (2log10 of p-value) on the y-axis
versus SNPs according to their position in the genome on the x-axis (build 36). The most interesting candidate genes are highlighted.
doi:10.1371/journal.pgen.1000672.g001
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atherosclerotic plaque formation, myocardial infarction (MI),
cardiomyopathy, pancreatic beta cell failure, insulin resistance
and type 2 diabetes mellitus (T2D) [15]. Until now, the genetic
variants that influence circulating sphingolipid concentrations in
the general population have been characterized in relatively small
cohorts [8]. Here we identified genetic variation with a significant
effect on the biosynthesis, metabolism or intracellular trafficking of
some of the major sphingolipids species in a large diverse group of
European population samples. The SNPs showing association with
circulating sphingolipids explain up to 10.1% of the population
variation in each trait and 14.2% of some matched ratios (Tables
S2 and Table S4). Four of the five loci identified contain genes
encoding proteins that are either responsible for de novo ceramide
synthesis or for ceramide re-synthesis from sphingosine/sphinga-
nine-phosphates or both (SPTLC3, LASS4, FADS1–3 and SGPP1).
Increases in all of these enzymatic activities are predicted to
elevate the ‘‘ceramide-pool’’. The associations are observed not
only with ceramides, but also with sphingomyelins, indicating that
a considerable proportion of ceramide is converted into the large
and more stable ‘‘sphingomyelin-pool’’. None of the genes
involved in ceramide degradation or ceramide-related signaling
is genome-wide significantly associated with the traits analyzed,
indicating the primary role of genes related to ceramide
production in the genetic control of ceramide levels. Of these
four loci, the FADS1–3 gene cluster has been the most frequently
to be reported linked with disease in recent literature. Variants
within in this region have been associated with cardiovascular
disease and classic lipid risk factors such as cholesterol levels
[10,13,14]. Reported variants demonstrating association in these
reports (rs174547, rs174570, rs174537 and rs174546) are within
the FADS1 and FADS2 genes, but expression studies indicate
complex regulation in this region, with the FADS1 SNP rs174547
showing correlation with expression of both FADS1 and FADS3
genes [19], while the FADS1 SNP rs174546 correlates with FADS1
but not FADS2 expression [10]. Our strongest associations with
both sphingolipid levels and MI are in or nearest the FADS3 gene,
with variants showing less marked association with cholesterol
levels than that observed with variants over FADS1 and FADS2
genes (Table S7). It is known that sphingomyelin and ceramides
can modulate the atherogenic potential of LDL [20]. Further
functional studies will be necessary to determine whether the
active mechanism is through FADS3 alone, or in concert with
FADS1, FADS2 or both.
Neurological phenotypes associated with FADS2 include
attention-deficit/hyperactivity disorder [21] and the moderation
of breastfeeding effects on IQ [22]. Little is published regarding
disease association with variants at the other four major loci
described here. However, a reported association between
Figure 2. Detailed views of the 5 genomic regions demonstrating significant signals. (A–E) show the 5 regions individually with a
representation of all genes near the significant signals and the underlying linkage disequilibrium block structure in the HapMap CEU data (from the
UCSC genome browser). Thresholds for significance are indicated by a line.
doi:10.1371/journal.pgen.1000672.g002
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expression levels of SGPP1 with Schizophrenia [23] along with
changes in SPTLC2 (with variants identified in our candidate SNP
search –Table S4) and ASAH1, highlights the importance of testing
variants in these genes with multiple neurological and psychiatric
diseases. Additional neurological associations with candidate genes
listed in Table S4 include SGPL1 in Alzheimer’s disease [24] and
GBA with Parkinson’s disease and dementia with Lewy bodies
[25,26]. The wider possible involvement of genes within pathways
of ceramide metabolism in Lewy body disease has also been
recently reviewed [27].
The fifth locus contains ATP10D, a cation transport ATPase (P-
type) type IV subfamily member. The type IV subfamily is thought
to be an important regulator of intracellular serine-phospholipid
trafficking however the exact function or transport specificity of
ATP10D has not yet been described [9]. A novel functional finding
of this study is the specificity of the association of ATP10D SNPs to
glucosylceramides (among the species tested so far), which provides
the first evidence for the functional involvement of ATP10D in
intracellular transport of specific species of ceramide (Figure 3).
Impaired function of ATP10D may therefore lead to enhanced
exposure of ceramide to glucosyltransferases, forming higher
concentrations of glycosylceramides that are released into the
plasma compartment or may elevate serum glucosylceramide
concentrations by impaired transport of glycosylceramide to the
trans Golgi network. Mutations of ATP10D (C57BL/6J(B6)) in
mice result in low HDL concentrations and these mice develop
severe obesity, hyperglycaemia and hyperinsulinaemia when fed
on a high-fat diet [28]. Based on the mouse model, increased
circulating glucosylceramides in connection with ATP10D function
would be one plausible mechanism of contributing to weight gain
and early insulin resistance. From the novel association of SNPs in
ATP10D to MI (Table 2) seen in German studies, further
investigation of the specific role of glucosylceramides in MI and
other cardiovascular diseases is warranted.
Thus, sphingolipids play a role in pathological processes leading
to common complex diseases, and identification of genetic variants
that influence the balance between individual sphingolipid species
is an important first step into dissecting out the genetic
components in such processes. Associations between the SNPs
identified in this study, some of which have a strong effect on the
circulating plasma levels, and complex metabolic, cardiovascular,
inflammatory and neurological diseases in which a role for a
sphingolipid-dependent mechanism is implicated can now be
investigated. Modulation of sphingolipids in vivo has demonstrated
that this may be a successful preventative strategy for diseases in
which sphingolipids play a role, lending hope that, once such
disease contributions are identified, successful therapeutic regimes
may subsequently be identified.
Materials and Methods
Ethics statement
All studies were approved by the appropriate Research Ethics
Committees. The Northern Swedish Population Health Study
(NSPHS) was approved by the local ethics committee at the
University of Uppsala (Regionala Etikpro¨vningsna¨mnden, Up-
psala). The ORCADES study was approved by the NHS Orkney
Research Ethics Committee and the North of Scotland REC. The
Vis study was approved by the ethics committee of the medical
faculty in Zagreb and the Multi-Centre Research Ethics
Committee for Scotland. The ERF study was approved by the
Erasmus institutional medical-ethics committee in Rotterdam, The
Netherlands. The MICROS study was approved by the ethical
committee of the Autonomous Province of Bolzano. For the
German MI studies (GerMIFS-I,-II and –III(KORA), local ethics
committees approved the studies and written informed conset
obtained as published previously.
Study populations
The ERF study is a family-based study which includes over
3000 participants descending from 22 couples living in the
Rucphen region in the 19th century. All descendants were invited
to visit the clinical research center in the region where they were
examined in person and where blood was drawn (fasting). Height
Figure 3. Major sphingolipid synthesis and trafficking pathways. Biosynthetic pathways are shown along with the position in these
pathways of enzymes encoded by the genes giving statistically significant associations for circulating sphingolipid concentrations.
doi:10.1371/journal.pgen.1000672.g003
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and weight were measured for each participant. All participants
filled out questionnaire on risk factors, including smoking. The 800
participants included in the lipidomics studies consisted of the first
series of participants.
The MICROS study is part of the genomic health care program
‘GenNova’ and was carried out in three villages of the Val Venosta
on the populations of Stelvio, Vallelunga and Martello. This study
was an extensive survey carried out in South Tyrol (Italy) in the
period 2001–2003. An extensive description of the study is
available elsewhere [29]. Briefly, study participants were volun-
teers from three isolated villages located in the Italian Alps, in a
German-speaking region bordering with Austria and Switzerland.
Due to geographical, historical and political reasons, the entire
region experienced a prolonged period of isolation from
surrounding populations. Information on the health status of
participants was collected through a standardized questionnaire.
Laboratory data were obtained from standard blood analyses.
Genotyping was performed on just under 1400 participants with
1334 available for analysis after data cleaning. All participants
were included in the lipidomics studies.
The Swedish samples are part of the Northern Swedish
Population Health Study (NSPHS) representing a family-based
population study including a comprehensive health investigation
and collection of data on family structure, lifestyle, diet, medical
history and samples for laboratory analyses. Samples were
collected from the northern part of the Swedish mountain region
(County of Norrbotten, Parish of Karesuando). Historic popula-
tion accounts show that there has been little immigration or other
dramatic population changes in this area during the last 200 years.
The Orkney Complex Disease Study (ORCADES) is an
ongoing family-based, cross-sectional study in the isolated Scottish
archipelago of Orkney. Genetic diversity in this population is
decreased compared to Mainland Scotland, consistent with the
high levels of endogamy historically. Data for participants aged 18
to 100 years, from a subgroup of ten islands, were used for this
analysis. Fasting blood samples were collected and over 200
health-related phenotypes and environmental exposures were
measured in each individual. All participants gave informed
consent and the study was approved by Research Ethics
Committees in Orkney and Aberdeen.
The Vis study includes a 986 unselected Croatians, aged 18–93
years, who were recruited into the study during 2003 and 2004
from the villages of Vis and Komiza on the Dalmatian island of
Vis [30,31]. The settlements on Vis island have unique population
histories and have preserved their isolation from other villages and
from the outside world for centuries. Participants were phenotyped
for 450 disease-related quantitative traits. Biochemical and
physiological measurements were performed, detailed genealogies
reconstructed, questionnaire of lifestyle and environmental
exposures collected, and blood samples and lymphocytes extracted
and stored for further analyses. Samples in all studies were taken in
the fasting state.
Lipidomics
Lipids were quantified by electrospray ionization tandem mass
spectrometry (ESI-MS/MS) in positive ion mode as described
previously [32,33]. EDTA plasma (serum for South Tyrol)
samples were quantified upon lipid extraction by direct flow
injection analysis using the analytical setup described by Liebisch
et al. [33]. A precursor ion scan of m/z 184 specific for
phosphocholine containing lipids was used for phosphatidylcho-
line (PC) and sphingomyelin (SM) [33]. Ceramide and hex-
osylceramide were analyzed using a fragment ion of m/z 264
[32]. For each lipid class two non-naturally occurring internal
standards were added and quantification was achieved by
calibration lines generated by addition of naturally occurring
lipid species to plasma. Deisotoping and data analysis for all lipid
classes was performed by self programmed Excel Macros
according to the principles described previously [33]. Nomen-
clature of sphingomyelin species is based on the assumption that
d18:1 (dihydroxy 18:1 sphingosine) is the main base of plasma
sphingomyelin species, where the first number refers to the
number of carbon atoms in the chain and the second number to
the number of double bonds in the chain.
Genotyping
DNA samples were genotyped according to the manufacturer’s
instructions on Illumina Infinium HumanHap300v2 (except for
samples from Vis for which version 1 was used) or Hu-
manCNV370v1 SNP bead microarrays. Four populations have
318,237 SNP markers in common that are distributed across the
human genome, with Vis samples having 311,398 SNPs in
common with the other populations. Samples with a call rate
below 97% were excluded from the analysis. Sphingolipid
measurements were available for analysis following quality control
assessment for 4110 study participants.
Statistical analysis
Genome-wide association analysis was performed using the
GenABEL package in R [34]. A score test was used to test for
association between the age- and sex-adjusted residuals of
sphingolipid traits (both as absolute concentrations and as relative
content of the total sphingolipid pool: mol%) and SNP genotypes
using an additive model. The Genomic Control procedure [35]
was used to account for under-estimation of the standard errors of
effects, which occurs because of pedigree structure present in the
data [36]. For the most interesting results and the species ratios, we
re-analysed the data using ‘‘mmscore’’ function, a score test for
family-based association [37], as implemented in GenABEL. The
relationship matrix used in analysis was estimated using genomic
data with ‘‘ibs’’ (option weight = ‘‘freq’’) function of GenABEL.
This analysis, accounting for pedigree structure in an exact
manner, allowed for unbiased estimation of the effects of the
genetic variants (adjusted for age and sex). The results from all
cohorts were combined into a fixed-effects meta-analysis with
reciprocal weighting on standard errors of the effect-size estimates,
using MetABEL (http://mga.bionet.nsc.ru/,yurii/ABEL/).
Thresholds for genome wide significance were set at a p value of
less than 1.5761027 (0.05/318,237 SNPs) for the individual
populations. For the overall meta-analysis we chose to use the
conservative threshold of 7.261028 [38]. Since many of the traits
tested and especially the ratios demonstrate high degrees of
correlation, introducing a suitable statistical correction the
multiple testing of the 76 correlated traits would be complex.
Since Bonferroni correction (unsuitable in this instance) would
lower thresholds to values between p= 1029 to 10210, and since all
five genomic regions have variants with p values ,10210, we
report the age-sex corrected p values alone. The threshold for
replication of significant results from one population in other
cohorts was set at a p-value less than 0.05 divided by the number of
SNPs tested. All significant variants reported are in Hardy-
Weinberg Equilibrium, and effect directions are consistent across
all five populations.
Supporting Information
Table S1 Variants significantly associated with circulating
sphingolipid concentrations. 22 variants in 5 distinct chromosomal
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locations demonstrate genome-wide significant association signals
with several measured sphingolipid species (listed). The p-values
for significant signals across the sphingolipid species are shown for
each population separately and jointly, and the direction of the
association effects, as derived from the standardized regression
coefficient (b), is provided. Abbreviations, sphingomyelin (SM),
dihydrosphingomyelin (dihSM), ceramide (Cer) and glucosylcer-
amide (GluCer) unsaturated ceramides (CerUnsat), saturated
ceramides (CerSat). In the nomenclature (e.g. GluCer18:0), the
number before the colon refers to length of the carbon chain and
the number after the colon to the number of double bonds in the
chain. Where mol% is used, the measure refers to the relative
content of the measured species in the total sphingolipid pool, and
is independent of other associated lipid species. Sex-specific age
adjusted analyses provided little additional information, unlike the
case of the ratio analyses (see Table S3), and is not shown.
Found at: doi:10.1371/journal.pgen.1000672.s001 (0.28 MB
XLS)
Table S2 Variance in circulating sphingolipid concentrations.
The upper part of the table shows p-values (NS - not significant p-
value .0.05) estimated using a multiple regression model. The
bottom part of the table, shows the fraction of variance of the traits
explained by sex, age and all the significant SNPs from the
regression model.
Found at: doi:10.1371/journal.pgen.1000672.s002 (0.06 MB
XLS)
Table S3 Variants significantly associated with matched metab-
olite sphingolipid ratios. 32 variants in 5 distinct chromosomal
locations demonstrate genome-wide significant association signals
with matched metabolite ratios designed to probe metabolism (11
ratios), desaturation (16 ratios) and elongation (16 ratios) - details
of the ratios are provided in the table. The p-values for significant
signals across the sphingolipid species are shown for each
population separately and jointly, and the direction of the
association effects, as derived from the standardized regression
coefficient (b), is provided. Sex-specific age adjusted results are also
displayed, as these provided additional information with the ratio
analysis that was more significant than the sex-specific effects seen
in the analysis of the single species (not shown).
Found at: doi:10.1371/journal.pgen.1000672.s003 (0.09 MB
XLS)
Table S4 Proportion of variance in matched shpingolipid
metabolite ratios. Proportion of the variance in age and sex
adjusted sphingolipid ratio explained by SNP variants that were
significant in the GWA metanalysis of the 5 EUROSPAN
populations. General linear mixed models were fitted using the
polygenic function of the R statistical package ‘‘GenABEL’’ and
variances explained drawn from comparing residual variances
between models fitting in the SNP tested as fixed effects and
models not fitting them in. Single SNP analysis were carried out
for all candidate SNP, and multiple SNP for traits influenced by
multiple candidate regions (in this case the top SNP for each
region was selected). Shaded cells indicate SNP with GWA
significant association in the meta-analysis for the trait analysed.
Found at: doi:10.1371/journal.pgen.1000672.s004 (0.03 MB
XLS)
Table S5 Signals over SNPs within candidate sphingolipid
genes. Using a dataset of 624 SNPs within or near 40 genes
encoding enzymes and transporters involved in pathways of
sphingolipid metabolism, association results were extracted from
both the single sphingolipid GWAS runs, or those with the
matched metabolite ratios. In total 70 variants within and around
23 of these genes demonstrate p values of 1024 or less, making
them interesting targets for further study.
Found at: doi:10.1371/journal.pgen.1000672.s005 (0.09 MB
XLS)
Table S6 Table of phenotypic correlations between traits.
Pearson correlations of age and sex adjusted measures were
calculated and only significant values (2 tailed p-values ,= 0.05)
represented. Traits included all sphingolipids species, some
anthropometric measures: weight, bmi and height, blood pressure
(sbp = systolic blood pressure, dbp = diastolic blood pressure),and
classical circulating lipoproteins species tc = total cholesterol,
ldl = LDL cholesterol, hdl = HDL-cholesterol, tri = Triglycerides.
Found at: doi:10.1371/journal.pgen.1000672.s006 (0.40 MB
XLS)
Table S7 Association signals for sphingolipid SNPs with classical
lipids. Signals were extracted from age-sex adjusted or age
adjusted sex specific GWAS scans across the EUROSPAN
populations for the traits: HDL- and LDL-cholesterol, Triglycer-
ides (tri) and Total Cholesterol (tc).
Found at: doi:10.1371/journal.pgen.1000672.s007 (0.26 MB
XLS)
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